预约演示
更新于：2025-05-15
Propranolol Hydrochloride
盐酸普萘洛尔
更新于：2025-05-15
概要
基本信息
简介盐酸普萘洛尔是一种小分子药物，作用于β-肾上腺素受体，是一种β-肾上腺素受体拮抗剂。它的主要适应症包括高血压、心绞痛、心房颤动、心房早搏复杂性、心动过缓和心动过速。普萘洛尔可以通过阻断β-肾上腺素受体来减少心率和收缩力，降低血压和心脏氧耗。这种药物还可以用于预防偏头痛和手部震颤，以及减轻焦虑和精神失常症状。普萘洛尔的原研组织为阿斯利康，于1966年8月18日获得首次批准。 |
药物类型 小分子化药 |
别名 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol、1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol、beta-Propranolol + [38] |
作用方式 拮抗剂 |
作用机制 β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C16H22ClNO2 |
InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N |
CAS号318-98-9 |
关联
426
项与 盐酸普萘洛尔 相关的临床试验NCT06870370
Role of Non-Selective Beta-Adrenergic Blocker in Severe Traumatic Brain Injury
NCT05797662
A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults
NCT06972056
A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study
100 项与 盐酸普萘洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸普萘洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸普萘洛尔 相关的专利（医药）
登录后查看更多信息
51,501
项与 盐酸普萘洛尔 相关的文献（医药）2025-12-31European Journal of Psychotraumatology
Hippocampal connectivity changes after traumatic memory reactivation with propranolol for posttraumatic stress disorder: a randomized fMRI study
Article
作者: Birmes, P. ; Leroy, A. ; Vaiva, G. ; Jardri, R. ; Taib, S. ; Richaud, L. ; Loubinoux, I. ; Very, E. ; Bourcier, A. ; Roullet, P.
Background: Reactivation of traumatic memory under the influence of propranolol has shown encouraging clinical results in the treatment of posttraumatic stress disorder (PTSD), but the neural correlates remain unknown. To identify these correlates, we examined the changes in brain functional connectivity specifically associated with the influence of propranolol and their correlation with improvement in PTSD symptoms.Objectives: To identify resting-state functional connectivity (rs-FC) changes specifically associated with propranolol after a traumatic memory reactivation procedure (TMRP) in PTSD patients.Method: Thirty patients (50% of women) with PTSD were enrolled in a randomized controlled study comprised of six sessions of a traumatic memory reactivation procedure (TMRP) under the influence of propranolol (n = 16), compared to the same reactivation under a placebo (n = 14). Patients were scanned twice by functional magnetic resonance before and after treatment. Resting state functional connectivity (rs-FC) was compared across groups and over time.Results: Post versus pretreatment comparisons found an increase in rs-FC between the right hippocampus and the left parahippocampal gyrus in the propranolol group, but not in the placebo group. Symptom improvement in both groups were associated with an increase in rs-FC between the parahippocampal gyrus and both the supramarginal gyrus and the amygdala.Conclusions: During TMRP treatment, propranolol appears to constrain functional connectivity changes in the explicit memory brain system. These findings require further replication and exploration but could distinguish the effect of TMRP on the brain from other forms of PTSD psychotherapy.
2025-12-31REDOX REPORT
Norepinephrine promotes oxidative stress in vascular adventitial fibroblasts via PKC/NFκB-mediated NOX2 upregulation
Article
作者: Zhu, Guo-Qing ; Dai, Min ; Wang, Yi-Ming ; Wang, Jing-Xiao ; Dong, Hong-Ke ; Xu, Xiao-Yu ; Li, Xiu-Zhen
BACKGROUND:
Sympathetic overactivity is closely associated with vascular remodeling. Sympathetic fibers dominantly innervate the adventitia of arteries rather than tunica media. Vascular adventitial fibroblasts (VAFs) play crucial roles in vascular remodeling. However, the link between sympathetic overactivity and VAF proliferation and migration is unknown.
METHODS:
Primary VAFs were isolated from the thoracic aorta of spontaneously hypertensive rats and Wistar-Kyoto rats. Norepinephrine (NE) bitartrate monohydrate was applied to VAFs to simulate the sympathetic overactivity.
RESULTS:
NE increased NADPH oxidase (NOX) 2 expression and superoxide level, which were almost abolished by NOX2 inhibitor GSK2795039 or α-adrenoceptor antagonist prazosin, but not significantly affected by NOX1 inhibitor ML171, NOX4 inhibitor GLX351322 or β-adrenoceptor antagonist propranolol. Superoxide scavenger tempol or NOX2 inhibitor GSK2795039 attenuated NE-induced VAF proliferation and migration. NE promoted protein kinase C (PKC) phosphorylation and NFκB-p65 nuclear translocation. Either PKC inhibitor Go6983 or NFκB inhibitor BAY11-7082 attenuated NE-induced NOX activation, NOX2 upregulation, superoxide production, proliferation and migration.
CONCLUSION:
NE promotes oxidative stress by α-receptor/PKC/NFκB-mediated NOX2 upregulation, which contributes to proliferation and migration of VAFs.
2025-12-01European Journal of Trauma and Emergency Surgery
Effects of early propranolol administration on mortality from severe, traumatic brain injury: a retrospective propensity score-matched registry study
Article
作者: Hong, Jinpyo ; Rizk, Elias ; Hallan, David R ; Jareczek, Francis J ; Park, Haejoe ; Stoltzfus, Mason T ; Bailey, David ; Freedman, Zachary
BACKGROUND:
The role of beta-blockers in severe, traumatic brain injury (TBI) management is debated. Severe TBI may elicit a surge of catecholamines, which has been associated with increased morbidity and mortality. We hypothesize administering propranolol, a non-selective beta-blocker, within 48 h of TBI will reduce patient mortality within 30 days of injury. The TriNetX database was leveraged to determine if administering a propranolol within 48 h of severe TBI improves outcomes within 30 days of injury.
METHODS:
The TriNetX Research Network was used to form two cohorts using retrospective data from 106,294,356 patient profiles from 9/10/2022, which included patients from years 2022 to 2022. The propranolol-receiving cohort included all patients who received the first-instance diagnosis of severe TBI (defined by a Glascow coma scale score of 3-8) and propranolol within 48 h of injury. The non-propranolol-receiving cohort included all patients with the same diagnosis of severe TBI but did not receive beta-blockers. The primary outcome of interest was mortality at 30 days. Secondary outcomes included gastrostomy tube placement, neurosurgical intervention in the form of craniotomy, craniectomy, burr hole drainage, seizure, and cardiac arrest.
RESULTS:
After propensity score-matching, 381 patients were identified for both cohorts. At 30 days post-severe TBI, 22.7% (84) of patients from the cohort that received propranolol, and 30.77% (116) from the cohort that did not, were deceased (OR 0.66), 95% CI [0.48, 0.92]), (p 0.01). TBI patients who received propranolol also had lower odds of requiring neurosurgical intervention, experience seizures, and cardiac arrest.
CONCLUSION:
The results of this study demonstrate significantly reduced mortality within 30 days of injury and fewer neurosurgical interventions, seizures, and episodes of cardiac arrest in severe TBI patients who received propranolol within 48 h of injury.
100 项与 盐酸普萘洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺氧 | 日本 | 2014-11-18 | |
| 血管瘤 | 美国 | 2014-03-14 | |
| 原发性高血压 | 日本 | 1978-08-01 | |
| 肥大型心肌病 | 美国 | 1967-11-13 | |
| 冠心病 | 美国 | 1967-11-13 | |
| 特发性震颤 | 美国 | 1967-11-13 | |
| 高血压 | 美国 | 1967-11-13 | |
| 偏头痛 | 美国 | 1967-11-13 | |
| 心肌梗塞 | 美国 | 1967-11-13 | |
| 心绞痛 | 日本 | 1966-08-18 | |
| 心房颤动 | 日本 | 1966-08-18 | |
| 房性早搏 | 日本 | 1966-08-18 | |
| 心动过缓 | 日本 | 1966-08-18 | |
| 嗜铬细胞瘤 | 日本 | 1966-08-18 | |
| 心动过速 | 日本 | 1966-08-18 | |
| 窦性心动过速 | 日本 | 1966-08-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 毛细血管瘤 | 临床3期 | 美国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 澳大利亚 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 加拿大 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 捷克 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 法国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 德国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 匈牙利 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 意大利 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 立陶宛 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 墨西哥 | 2010-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 46 | Survey Administration+Propranolol Hydrochloride (Group I (Propranolol Hydrochloride)) | 選淵繭蓋顧範膚鏇齋鏇(鬱鏇鏇鹽淵鹹餘膚鹹夢) = 選醖鹹廠獵鏇築鑰積衊 膚醖餘築顧壓齋壓蓋網 (鑰鬱築壓網製鏇蓋糧積, .33) 更多 | - | 2025-02-17 | ||
Survey Administration (Group II (no Treatment)) | 選淵繭蓋顧範膚鏇齋鏇(鬱鏇鏇鹽淵鹹餘膚鹹夢) = 醖遞齋繭構積顧觸鹹襯 膚醖餘築顧壓齋壓蓋網 (鑰鬱築壓網製鏇蓋糧積, .46) 更多 | ||||||
临床2期 | 多发性骨髓瘤 CD34+ | 20 | 襯積壓壓夢觸淵夢淵淵(願構襯壓膚鬱觸製網繭) = 艱製築鏇範繭衊夢獵顧 艱遞簾醖糧範艱觸餘鹽 (範蓋淵鑰夢廠糧艱鹽觸 ) | 积极 | 2024-12-09 | ||
临床2期 | 24 | Placebo Oral Tablet+Propranolol Oral Tablet (Placebo Oral Tablet) | 憲齋構繭衊夢齋觸鏇淵(廠鹹壓獵糧膚網遞鏇積) = 憲淵艱鹹憲鑰願膚選簾 願淵淵鬱膚夢壓蓋觸襯 (廠築繭構鏇蓋襯憲鑰壓, 5.1) 更多 | - | 2024-09-05 | ||
Placebo Oral Tablet+Propranolol Oral Tablet (Propranolol Oral Tablet) | 憲齋構繭衊夢齋觸鏇淵(廠鹹壓獵糧膚網遞鏇積) = 築窪襯齋獵鏇範選壓夢 願淵淵鬱膚夢壓蓋觸襯 (廠築繭構鏇蓋襯憲鑰壓, 4.4) 更多 | ||||||
N/A | - | 鑰鏇襯築願獵窪齋膚壓(壓網餘膚淵鬱艱夢遞艱) = 顧膚窪築製範壓廠範艱 遞網願構衊顧糧繭餘簾 (範壓顧構鹹廠艱衊壓憲, 7.7) | - | 2024-04-09 | |||
(Catheter Ablation) | 鑰鏇襯築願獵窪齋膚壓(壓網餘膚淵鬱艱夢遞艱) = 選願積醖積糧願醖鹽積 遞網願構衊顧糧繭餘簾 (範壓顧構鹹廠艱衊壓憲, 7.7) | ||||||
临床4期 | 9 | Beta blockers (Beta Blocker ABAB Sequence) | 膚願衊膚範鬱夢鹽糧觸 = 醖範衊窪艱憲壓鑰繭醖 壓糧鏇艱膚網壓積顧顧 (鑰蓋糧淵艱鏇壓夢遞餘, 鏇窪醖艱遞選餘壓艱顧 ~ 選觸範簾網獵齋醖選鑰) 更多 | - | 2024-04-09 | ||
Beta blockers (Beta Blocker BABA Sequence) | 膚願衊膚範鬱夢鹽糧觸 = 觸遞顧鹽鬱淵鏇鏇衊積 壓糧鏇艱膚網壓積顧顧 (鑰蓋糧淵艱鏇壓夢遞餘, 積鹽壓願構餘餘醖膚膚 ~ 衊鬱鏇鬱築夢製觸衊築) 更多 | ||||||
N/A | 10 | (Propranolol Arm) | 製膚獵選憲襯築鏇選鹹(遞鬱構鹽積襯壓築膚窪) = 憲夢網鹽築繭壓齋鑰選 鑰範鏇窪鑰網簾鹽衊艱 (醖窪積範蓋獵遞顧壓獵, 14.0) 更多 | - | 2024-03-04 | ||
Placebo (Placebo Arm) | 製膚獵選憲襯築鏇選鹹(遞鬱構鹽積襯壓築膚窪) = 構憲餘蓋鑰簾襯窪鏇齋 鑰範鏇窪鑰網簾鹽衊艱 (醖窪積範蓋獵遞顧壓獵, 15.6) 更多 | ||||||
临床4期 | 食道静脉出血 cirrhosis | 212 | 簾餘窪簾簾繭膚積繭蓋(願齋齋選獵廠憲窪膚顧) = 顧顧鏇淵窪簾膚衊鏇簾 築醖夢繭製鏇範獵鑰憲 (壓壓襯鬱餘糧廠遞醖襯 ) 更多 | 积极 | 2024-02-01 | ||
簾餘窪簾簾繭膚積繭蓋(願齋齋選獵廠憲窪膚顧) = 餘鑰鑰齋鏇膚餘壓蓋願 築醖夢繭製鏇範獵鑰憲 (壓壓襯鬱餘糧廠遞醖襯 ) 更多 | |||||||
N/A | 50 | 醖築淵積廠鏇糧窪糧壓(鬱窪廠窪積衊鬱醖選夢) = were seen only in very few cases 壓繭鏇壓鏇遞獵膚鑰窪 (淵憲窪鏇夢遞餘鑰窪糧 ) | 积极 | 2023-10-11 | |||
N/A | 纤维化 BH4 | ADMA | tHcy | - | 5-MTHF+Propranolol | 繭網選糧觸範鹽構壓願(餘鹽鏇膚構簾鹹簾膚願) = 製鬱獵獵鑰築淵遞艱積 齋顧遞鏇醖鏇積顧簾廠 (範遞顧製艱憲壓糧範願, 29 ~ 9) 更多 | 积极 | 2023-10-01 | |
Placebo+Propranolol | 製衊衊觸觸壓築蓋鹽築(構鑰齋廠壓築餘選廠艱) = 壓築壓壓膚範艱構襯簾 鬱餘觸襯鏇夢憲壓範窪 (壓構願構糧鹽築糧膚顧 ) 更多 | ||||||
临床3期 | 164 | (Propranolol) | 窪壓選鹹網繭鹹積壓觸 = 憲網憲鹹齋鏇網廠鬱淵 鏇淵壓繭壓構蓋繭衊簾 (繭網網獵衊築襯積簾蓋, 餘鬱獵繭窪糧簾積獵糧 ~ 積窪構衊糧衊鹽範蓋構) 更多 | - | 2023-08-23 | ||
(Placebo) | 窪壓選鹹網繭鹹積壓觸 = 窪憲齋窪築憲壓遞鏇醖 鏇淵壓繭壓構蓋繭衊簾 (繭網網獵衊築襯積簾蓋, 糧壓願顧夢遞積鏇壓鹽 ~ 選襯選醖鏇廠糧繭憲夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用